Arginase-1 targeting peptide vaccine in patients with metastatic solid tumors - A phase I trial.

ABSTRACT:

Background

Arginase-1-producing cells inhibit T cell-mediated anti-tumor responses by reducing L-arginine levels in the tumor microenvironment. T cell-facilitated elimination of arginase-1-expressing cells could potentially restore L-arginine levels and improve anti-tumor responses. The activation of arginase-1-specific T cells may convert the immunosuppressive tumor microenvironment and induce or strengthen local Th1 inflammation. In the current clinical study, we examined the safety and immunogenicity of arginase-1-based peptide vaccination.

Methods

In this clinical phase I trial, ten patients with treatment-refractory progressive solid tumors were treated. The patients received an arginase-1 peptide vaccine comprising three 20-mer peptides from the ARG1 immunological "hot

SUBMITTER: Lorentzen CL 

PROVIDER: S-EPMC9622376 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature